Validación de método cromatográfico por HPLC de la valoración e identificación del (1-(1β, 16α)-21-(acetiloxi)-11-hidroxi-2´-metil-5´H-pregna-1,4-dieno[17,16-d]oxazol-3,20-diona) en Deflazacort materia prima

Validación de método cromatográfico por HPLC de la valoración e identificación del (1-(1β, 16α)-21-(acetiloxi)-11-hidroxi-2´-metil-5´H-pregna-1,4-dieno[17,16-d]oxazol-3,20-diona) en Deflazacort materia prima

Introduction. Deflazacort (DFZ) is a synthetic ozaxolinic glucocorticoid derived from prednisolone, it has anti-inflammatory properties and acts as an immunosuppressant, Deflazacort is the raw material used as the active ingredient of products marketed in pharmaceutical forms such as tablets and oral suspensions. Objective. The objective was to validate the methodology analytical by high performance liquid chromatography (HPLC), for the identification and assessment of (1-(1β,16α)-21-(acetyloxy)-11-hydroxy-2´-methyl-5´H-pregna-1,4 -dieno[17,16-d]oxazol-3,20-diona) in Deflazacort raw material under tropical climate conditions. Methodology. Using as mobile phase an isocratic mixture of methanol and water in a ratio of 80:20 with a flow of 1, 1mL/min, the column used was Luna® 5µm C8 100Ǻ 250 x 4.6mm, diode array detector at a wavelength of 245nm. Results: For linearity, a correlation coefficient R ≥ 0.999 was obtained, the coefficient of variation did not exceed the RS D of 2.0% in the repeatability of the system and in intermediate precision between analysts, an RSD value <3.0% was identified, in accuracy a recovery percentage of 98.9% was found.  Conclusions. The method is linear, precise, exact, robust for a flow of 1.21mL/min and not for a flow of 0.99mL/min since it does not meet retention time. In the performance tests, Deflazacort showed low stability when exposed to degradation by basic hydrolysis with 1.0 N and 0.1 N NaOH solutions. The sample and the standard in solution showed to be stable at room temperature for two hours and refrigerated for three hours.

1. Huber EW, Barbuch RJ. Spectral analysis and structural identification of a major deflazacort metabolite in man. Xenobiotica. 1995;25(2):175-83.
2. https://doi.org/10.3109/00498259509061843
4. Markham A, Bryson HM, Agnusdei D, Speciale P, Siena U, Gennari C, et al. and Therapeutic Efficacy Deflazacort. 1995;50(2):317-33.
5. https://doi.org/10.2165/00003495-199550020-00008
7. Özkan Y, Savaşer A, Taş Ç, Uslu B, Özkan SA. Drug dissolution studies and determination of deflazacort in pharmaceutical formulations and human serum samples by RP-HPLC. J Liq Chromatogr Relat Technol. 2003;26(13):2141-56.
8. https://doi.org/10.1081/JLC-120022399
10. Research Article Development and Characterization of Deflazacort Nanoparticles for the Treatment of Inflammatory Bowel Disease. 2021;14(2).
12. Cuffini SL, Ellena JF, Mascarenhas YP, Ayala AP, Sielser HW, Filho JM, et al. Physicochemical characterization of deflazacort: Thermal analysis, crystallographic and spectroscopic study. Steroids. 2007;72(3):261-9.
13. https://doi.org/10.1016/j.steroids.2006.11.020
15. Chourasiya Y, Maheshwari R, Tekade RK. Current developments in excipient science: Implication of quantitative selection of each excipient in product development. In: Basic Fundamentals of Drug Delivery. Elsevier; 2018. p. 29-83.
16. https://doi.org/10.1016/B978-0-12-817909-3.00002-9
18. Scremin A, Piazzon M, Silva MAS, Kuminek G, Correa GM, Paulino N, et al. Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms. Brazilian J Pharm Sci. 2010;46(2):281-7.
19. https://doi.org/10.1590/S1984-82502010000200015
21. Patel M, Jebaliya H, Dabhi B, Jadeja Y, Jani N, Desai D, et al. Chromatography method transfers from HPLC to a new generation instrument UPLC and studies on force degradation behavior of deflazacort. Der Pharm Lett. 2015;7(2):142-9.
23. Raju CK, Pandey AK, Ghosh K, Pola A, Goud SK, Jaywant MA, et al. Isolation and structural characterization of novel photolytic degradation impurities of Deflazacort using Q-TOF, 2D-NMR and FTIR. J Pharm Biomed Anal [Internet]. 2017;133:82-9. Available from: http://dx.doi.org/10.1016/j.jpba.2016.11.005
24. https://doi.org/10.1016/j.jpba.2016.11.005
26. Parente L. Deflazacort: Therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol [Internet]. 2017;18(1):1-8. Available from: http://dx.doi.org/10.1186/s40360-016-0111-8
27. https://doi.org/10.1186/s40360-016-0111-8
29. Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy. Ann Pharmacother. 2020;54(8):788-94.
30. https://doi.org/10.1177/1060028019900500
32. McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle and Nerve. 2020;61(1):26-35.
33. https://doi.org/10.1002/mus.26736
35. López A. E, Ramírez G. G, Iglesias G. A. Instituto Nacional de Vigilancia de Medicamentos y Alimentos: una muerte anunciada. Nova. 2004;2(2):94.
36. https://doi.org/10.22490/24629448.11
38. Salud MDE, Resoluci S, Salud ELMDE, En S, Que C, Unidos E, et al. La resolución 00001606, del ministerio de salud, 2014. 2014;
40. Moreno LB, Rafael C, Carballo R, Torrez GR. Validación del método cromatográfico para estudios de estabilidad del ciprofloxacino clorhidrato 0 , 2 % gota ótica Validation of the chromatographic method for stability studies of ciprofloxacin hydrochloride 0 , 2 % otic drop. 2022;55(1):1-14.
42. Borges LG. Evaluación de los métodos analíticos para el control de calidad de ampicilina y oxacilina Evaluation of the analytical methods for the quality control of ampicillin and oxacillin. 52(1):1-21.
44. Rodríguez DP, Orta IA, Pérez YS, López GJ. Quality defects during the marketing of pharmaceutical products and the role of regional regulatory authorities. Rev Cuba Farm. 2021;54(3):1-16.
46. YAPAR EA, ÖZDEMİRHAN ME. an Overview on Pharmacopoeias in the World and Monograph Elaboration Techniques. Univers J Pharm Res. 2020;5(3):57-64.
47. https://doi.org/10.22270/ujpr.v5i3.418
49. Guevara M, Mogollón L, Iglesias A, Yupanqui H, Bermúdez A. Estimación de Vitamina D en mujeres con osteopenia y osteoporosis en Cundinamarca-Colombia, por medio de extracción en fase sólida, cromatografía líquida de alta resolución y análisis multivariado. Nova. 2003;1(1):72.
50. https://doi.org/10.22490/24629448.1055
52. Corrêa GM, Bellé LP, Bajerski L, Borgmann SHM, Cardoso SG. Development and validation of a reversed-phase HPLC method for the determination of deflazacort in pharmaceutical dosage forms. Chromatographia. 2007;65(9-10):591-4.
53. https://doi.org/10.1365/s10337-007-0205-y
55. International Conference on Harmonisation. Validation of analytical procedures: test and methodology. Encycl Toxicol Third Ed. 1995;2(June 1995):1070-2.
57. USP/NF. Validación de procedimientos farmacopeicos. USP de los Estados Unidos de América; 2017. p. Capítulo 1225.
59. Bor M, Guilarte A, Guzmán L, Mendoza KMW. Validación de un método por RP-HPLC para la determinación de Tiocolchicósido en tabletas. Afinidad. 2018;75(581).
61. Bermúdez PhD M, Carrillo Bsc Y. Diagnóstico de Homocistinuria y Deficiencia de Adenilosuccinato Liasa a Través de Técnicas Químicas, Bioquímicas y Moleculares. Nova. 2005;3(3):46.
62. https://doi.org/10.22490/24629448.18
64. Waters. Empower 3 Software. 2010; 2010.
66. Inc, Thermo Fisher Scientific D. Chromeleon 7, Chromatography data system. 2009.
68. Chen Y, Xia L, Liang R, Lu Z, Li L, Huo B, et al. Advanced materials for sample preparation in recent decade. TrAC - Trends Anal Chem [Internet]. 2019;120:115652. Available from: https://doi.org/10.1016/j.trac.2019.115652
69. https://doi.org/10.1016/j.trac.2019.115652
71. Fischer Scientific. Por qué la filtración de muestras y de la fase móvil es esencial para el análisis de HPLC. Thermo Fischer Scientific. 2022. Tomo 22.036. Folio 17. Inscripción 1a, C.I.F. B-84498955
73. USP/NF. Cromatografía. Estados Unidos de América; 2017. p. Capítulo 621.
75. Farias FF, Martins VAP, Yano HM, Trujillo LM, Pinto E. Forced degradation studies to identify organic impurities in pharmaceuticals: A brazilian perspective. Rev Ciencias Farm Basica e Apl. 2021;42:1-13.
76. https://doi.org/10.4322/2179-443X.0729
78. Thorat SS, Gupta A. Basic Concept of Stability Profile and Stress Degradation Pathway of Pharmaceutical Formulations: A Review. J Biol Chem Chron. 2018;4(3):34-42.
80. Bhaskar R, Ola M, Agnihotri V, Chavan A, Girase H. Current Trend in Performance of Forced Degradation Studies for Drug Substance and Drug Product's. J Drug Deliv Ther. 2020;10(2-s):149-55.
81. https://doi.org/10.22270/jddt.v10i2-s.4040
83. Verbić T, Dorkó Z, Horvai G. Selectivity in analytical chemistry. Rev Roum Chim. 2013;58(7-8):569-75.
85. Avila J. Validación del método analítico de contenido e identificación de prednisolona sodio fosfato (base) en prednisolona 5mg/ml solución oral. [Internet]. Universidad Nacional de Trujillo; 2012. Available from: https://dspace.unitru.edu.pe/bitstream/handle/UNITRU/10406/Amaya Hilario Carmen Victoria.pdf?sequence=1&isAllowed=y
87. Divyashree S, Mk V, Kp C. Journal of Chronotherapy and Drug Delivery Method Validation for Simultaneous Estimation of Prednisolone and Abiraterone Acetate by RP-HPLC. J Chronother Drug Deliv . 2016;7:41-9.
89. María Díaz Peña Mara Sacristán San Cristóbal Borja Alarcón Aguareles Carlos Vicente Córdoba María Estrella Legaz González E. Curso de cromatografía de líquidos de alta resolución (HPLC): Prácticas de laboratorio y cuestiones teórico-prácticas. Parte II. Práctica de laboratorio: análisis cuantitativo básico. Reduca (Biología. 2011;4(3):33-47.
91. Sierra N, Gómez G. Desarrollo y validación de una metodología por cromatografía líquida de alta eficiencia para la determinación simultánea de piperacilina sódica y tazobactam sódico en inyectables para uso humano. Rev Colomb Ciencias Químico-Farmacéuticas. 2014;43(1):5-21.
92. https://doi.org/10.15446/rcciquifa.v43n1.45461
94. Kruve A, Rebane R, Kipper K, Oldekop ML, Evard H, Herodes K, et al. Tutorial review on validation of liquid chromatography-mass spectrometry methods: Part II [Internet]. Vol. 870, Analytica Chimica Acta. Elsevier B.V.; 2015. 8-28 p. Available from: http://dx.doi.org/10.1016/j.aca.2015.02.016
95. https://doi.org/10.1016/j.aca.2015.02.016
97. Ruiz Chatez DJ, Afanasjeva N. Método de cuantificación enzimática con DNS para ß-mananasa en soya y en un aditivo nutricional. Cienc y Agric. 2022;19(3):57-72.
98. https://doi.org/10.19053/01228420.v19.n3.2022.14621
100. Sustancias DAS, Productos YP. Q1a(r2). 2003;
102. Cámara MS., Guerrero F., Alasino A., Caro Y., De Zan MM. Desarrollo y validación de un método analítico indicativo de estabilidad por CLAR para la evaluación de la pureza cromatográfica y la cuantificación simultánea de ibuprofeno y su compuesto relacionado 4-isobutilacetofenona en materias primas. Rev Mex Ciencias Farm [Internet]. 2017;48(4°):59. Available from: http://www.redalyc.org/articulo.oa?id=57956617007
104. Waters. How do you set up the Purity Thresholds in Empower 3? [Internet]. Waters knowledge base. 2021. Available from: https://support.waters.com/KB_Inf/Empower_Breeze/WKB11215_How_do_you_set_up_the_Purity_Thresholds_in_Empower_3
106. Llinas H. Regresión Lineal simple: Pruebas de hipótesis. Rpubs. 2021.